Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBERTO extension study of ocrelizumab in multiple sclerosis
NL-OMON52500Phase 4Recruiting
- Sponsor
- Roche
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS), sponsored by Roche. Primary endpoint: Effectiveness and safety/tolerability of ocrelizumab. Started Nov 2018; status: recruiting.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON52500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52500.